Abstract
Abstract
Background
Myocardial ischemia-reperfusion injury (MIRI) is defined as the restoration of blood flow to the myocardium after a brief interruption of blood supply, causing more severe damage to the ischemic myocardium. However, currently, reperfusion therapy is the preferred therapy for ischemic cardiomyopathy, which undoubtedly causes MIRI, and thus it has become a challenging issue affecting the prognosis of coronary artery disease.
Methods
A search was conducted in the Web of Science Core Collection database for papers relevant to MIRI therapy published between 1 January 2000 and 1 October 2023. Bibliometric analyses were performed using VOSviewer and CiteSpace to elucidate the progress and hotspots.
Results
3304 papers from 64 countries, 2134 research institutions and 13,228 authors were enrolled in the study. Of these, China contributed the most papers and had the biggest impact, while the United States had the most extensive partnership. The Fourth Military Medical University was the primary research institution. The most valuable authors include Chattipakorn, Nipon, Chattipakorn, Siriporn c, Yang, Jian and Yang, Yang.
Conclusion
Over the past 20 years, research on MIRI therapies has made significant strides. Further studies are necessary to explore the interactions between various therapeutic options. Future investigations will emphasize nanocarriers, cardiac regeneration, and stem cell therapies. Our study identifies MIRI research hotspots from a bibliometric perspective, forecasts future trends, and offers fresh insights into MIRI therapy research.
Funder
The National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. WHO. Cardiovascular diseases (CVDs)https://www.who.int/news-room/fact-sheets/detail/cardiovasculardiseases, 2021.
2. Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017;389(10065):197–210. https://doi.org/10.1016/s0140-6736(16)30677-8.
3. Zhao TJ, Wu W, Sui LH, et al. Reactive oxygen species-based nanomaterials for the treatment of myocardial ischemia reperfusion injuries. Bioactive Mater. 2022;7:47–72. https://doi.org/10.1016/j.bioactmat.2021.06.006.
4. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121–35. https://doi.org/10.1056/NEJMra071667.
5. JENNINGS RB, SOMMERS HM, SMYTH GA et al. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol, 1960(70): p. 68–78.